4 results
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
The overall aim of the DALI study is to identify the best available measures to prevent GDM in an ongoing pregnancy, to provide a cost-benefit calculation of GDM prevention for health care systems, and to establish a pan-European cohort of mother-…
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.